THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE

被引：2
|
作者：
KALLIO, J
HUUPPONEN, R
PYYKKO, K
机构：
[1] Departments of Pharmacology and Clinical Pharmacology, University of Turku
来源：
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1990年 / 39卷 / 01期
关键词：
Chlorpropamide; Debrisoquine phenotype; Metabolism; Pharmacogenetics; Pharmacokinetics;
D O I：
10.1007/BF02657068
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码：93 / 95
页数：3
相关论文
共 50 条
  • [11] INFLUENCE OF DEBRISOQUINE HYDROXYLATION PHENOTYPE ON THE PHARMACOKINETICS OF MEXILETINE
    LLEDO, P
    ABRAMS, SML
    JOHNSTON, A
    PATEL, M
    PEARSON, RM
    TURNER, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (01) : 63 - 67
  • [12] DEBRISOQUINE OXIDATION PHENOTYPE IN A SPANISH POPULATION
    BENITEZ, J
    COBALEDA, J
    LOZANO, L
    ELENA, A
    CERMENO, JA
    MARIN, J
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 216 - 216
  • [13] IS THERE A LINK BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND LUNG-CANCER SUSCEPTIBILITY
    HORSMANS, Y
    DESAGER, JP
    HARVENGT, C
    BIOMEDICINE & PHARMACOTHERAPY, 1991, 45 (08) : 359 - 362
  • [14] DEBRISOQUINE OXIDATION PHENOTYPE DURING NEUROLEPTIC MONOTHERAPY
    MARTINES, C
    SPINA, E
    COBALEDA, J
    PINAS, B
    BENITEZ, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (05) : 1868 - 1869
  • [15] DEBRISOQUINE OXIDATION PHENOTYPE DURING NEUROLEPTIC MONOTHERAPY
    SPINA, E
    MARTINES, C
    CAPUTI, AP
    COBALEDA, J
    PINAS, B
    CARRILLO, JA
    BENITEZ, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (05) : 467 - 470
  • [16] LACK OF A RELATIONSHIP BETWEEN THE POLYMORPHISM OF DEBRISOQUINE OXIDATION AND LUNG-CANCER
    DUCHE, JC
    JOANNE, C
    BARRE, J
    DECREMOUX, H
    DALPHIN, JC
    DEPIERRE, A
    BROCHARD, P
    TILLEMENT, JP
    BECHTEL, P
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) : 533 - 536
  • [17] RELATION BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND MORPHOLOGICAL, BIOLOGICAL, AND PATHOLOGICAL VARIABLES IN A LARGE POPULATION
    VINCENTVIRY, M
    MULLER, J
    FOURNIER, B
    GALTEAU, MM
    SIEST, G
    CLINICAL CHEMISTRY, 1991, 37 (03) : 327 - 332
  • [18] DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
    BOOBIS, AR
    DAVIES, DS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) : 653 - 656
  • [19] METABOLISM OF PARACETAMOL AND PHENACETIN IN RELATION TO DEBRISOQUINE OXIDATION PHENOTYPE
    VERONESE, ME
    MCLEAN, S
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (06) : 547 - 552
  • [20] DEBRISOQUINE OXIDATION PHENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
    SPEIRS, CJ
    MURRAY, S
    DAVIES, DS
    MABADEJE, AFB
    BOOBIS, AR
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (01) : 101 - 109
12345